Is PLUS THERAPEUTICS, INC. (PSTV) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 6.5% / 30% | 7.0% / 30% | 1.1% / 30% | N/A | ✓ HALAL |
| DJIM | 6.5% / 33% | 7.0% / 33% | 1.1% / 33% | N/A | ✓ HALAL |
| MSCI | 50.8% / 33% | 54.4% / 33% | 8.6% / 33% | N/A | ✗ NOT HALAL |
| S&P | 6.5% / 33% | 7.0% / 33% | 1.1% / 33% | N/A | ✓ HALAL |
| FTSE | 50.8% / 33% | 54.4% / 33% | 8.6% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -60.7% | |
| Operating Margin | -420.0% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -83.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$21M |
| Free Cash Flow | -$21M |
| Total Debt | $821,000 |
| Debt-to-Equity | 20.5 |
| Current Ratio | 1.2 |
| Total Assets | $16M |
Price & Trading
| Last Close | $0.24 |
| 50-Day MA | $0.27 |
| 200-Day MA | $0.46 |
| Avg Volume | 9.7M |
| Beta | 0.8 |
|
52-Week Range
$0.16
| |
About PLUS THERAPEUTICS, INC. (PSTV)
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is PLUS THERAPEUTICS, INC. (PSTV) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), PLUS THERAPEUTICS, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is PLUS THERAPEUTICS, INC.'s debt ratio?
PLUS THERAPEUTICS, INC.'s debt ratio is 6.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 50.8%.
What are PLUS THERAPEUTICS, INC.'s key financial metrics?
PLUS THERAPEUTICS, INC. has a market capitalization of $41M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.